Takeaways: Gazyva’s reimbursement recommendation is a clear commercial win for Roche because it opens the door to public coverage in a high-need, specialty autoimmune market...
Takeaways MedExpress is adding another low-cost telehealth channel for generic semaglutide in Canada, which should increase competition among virtual clinics and make GLP‑1 access even easier fo...
Takeaways Vertex’s suzetrigine filing is important because it could bring Canada its first new acute pain drug class in more than 20 years, which would give hospitals and payers a non-...
Takeaways Hims & Hers is using generic semaglutide to anchor its Canadian weight‑loss and metabolic program, giving it a priced‑in, recurring revenue product at about CAD 149/month that...
Takeaways HEMGENIX has moved from theory to practice in Canada, with the first patient now treated outside a trial and public funding in place in Ontario and British Columbia. Market‑wise,...
Takeaways Optimi is using its Nasdaq uplist and 1‑for‑30 share consolidation to raise roughly 15 million US dollars at scale, then plow the cash into making and selling ...
Takeaways Phoenix and Raven are turning Canada’s new generic semaglutide approvals into immediate, retail-like access, which will likely accelerate GLP‑1 uptake beyond traditional bric...
Takeaways Blenrep’s pCPA negotiations are an important step toward broader Canadian access to a new multiple myeloma option, especially because the drug is being positio...
Takeaways Ontario’s first dedicated AI safety division could make PSHSA a more important player in workplace compliance by turning its expertise into scalable digital tools. The ...
Takeaways Orimed’s expanded PrLuxa‑D line should make vitamin D supplementation more flexible in Canada by covering a much wider dose range, which helps physicians match treatment to defici...